nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Sorafenib—thyroid cancer	0.539	1	CbGbCtD
Raltegravir—CCR1—Peptide GPCRs—TSHR—thyroid cancer	0.005	0.137	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CALCB—thyroid cancer	0.0026	0.0709	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—SST—thyroid cancer	0.00183	0.0499	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00158	0.0431	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—SST—thyroid cancer	0.00154	0.0421	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CALCB—thyroid cancer	0.00147	0.04	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CALCB—thyroid cancer	0.00133	0.0364	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00128	0.035	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00123	0.0335	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—TSHR—thyroid cancer	0.0012	0.0328	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CHST14—thyroid cancer	0.00113	0.0309	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—PTCH1—thyroid cancer	0.00102	0.0279	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SST—thyroid cancer	0.000935	0.0255	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CALCA—thyroid cancer	0.0009	0.0246	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CALCB—thyroid cancer	0.000787	0.0215	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TRIM33—thyroid cancer	0.000746	0.0204	CbGpPWpGaD
Raltegravir—Vomiting—Vandetanib—thyroid cancer	0.00068	0.0016	CcSEcCtD
Raltegravir—Eructation—Doxorubicin—thyroid cancer	0.00068	0.0016	CcSEcCtD
Raltegravir—Rash maculo-papular—Epirubicin—thyroid cancer	0.000679	0.0016	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—TSHR—thyroid cancer	0.000679	0.0185	CbGpPWpGaD
Raltegravir—Neoplasm—Epirubicin—thyroid cancer	0.000676	0.00159	CcSEcCtD
Raltegravir—Rash—Vandetanib—thyroid cancer	0.000675	0.00159	CcSEcCtD
Raltegravir—Dermatitis—Vandetanib—thyroid cancer	0.000674	0.00159	CcSEcCtD
Raltegravir—Headache—Vandetanib—thyroid cancer	0.00067	0.00158	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000658	0.00155	CcSEcCtD
Raltegravir—Blood urea increased—Doxorubicin—thyroid cancer	0.000653	0.00154	CcSEcCtD
Raltegravir—Mental disability—Epirubicin—thyroid cancer	0.000649	0.00153	CcSEcCtD
Raltegravir—Lymphadenopathy—Epirubicin—thyroid cancer	0.000636	0.0015	CcSEcCtD
Raltegravir—Nausea—Vandetanib—thyroid cancer	0.000635	0.0015	CcSEcCtD
Raltegravir—Dyspepsia—Sorafenib—thyroid cancer	0.000635	0.0015	CcSEcCtD
Raltegravir—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000629	0.00148	CcSEcCtD
Raltegravir—Decreased appetite—Sorafenib—thyroid cancer	0.000627	0.00148	CcSEcCtD
Raltegravir—Neoplasm—Doxorubicin—thyroid cancer	0.000625	0.00147	CcSEcCtD
Raltegravir—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000624	0.00147	CcSEcCtD
Raltegravir—Diabetes mellitus—Epirubicin—thyroid cancer	0.000624	0.00147	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000623	0.00147	CcSEcCtD
Raltegravir—Fatigue—Sorafenib—thyroid cancer	0.000622	0.00147	CcSEcCtD
Raltegravir—Pain—Sorafenib—thyroid cancer	0.000617	0.00145	CcSEcCtD
Raltegravir—Constipation—Sorafenib—thyroid cancer	0.000617	0.00145	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—TSHR—thyroid cancer	0.000617	0.0168	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000607	0.0166	CbGpPWpGaD
Raltegravir—Hepatic failure—Epirubicin—thyroid cancer	0.000604	0.00142	CcSEcCtD
Raltegravir—Mental disability—Doxorubicin—thyroid cancer	0.0006	0.00141	CcSEcCtD
Raltegravir—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00059	0.00139	CcSEcCtD
Raltegravir—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000589	0.00139	CcSEcCtD
Raltegravir—Hot flush—Epirubicin—thyroid cancer	0.00058	0.00137	CcSEcCtD
Raltegravir—Increased appetite—Epirubicin—thyroid cancer	0.000578	0.00136	CcSEcCtD
Raltegravir—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000577	0.00136	CcSEcCtD
Raltegravir—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000577	0.00136	CcSEcCtD
Raltegravir—Menopausal symptoms—Epirubicin—thyroid cancer	0.000575	0.00136	CcSEcCtD
Raltegravir—Urticaria—Sorafenib—thyroid cancer	0.000573	0.00135	CcSEcCtD
Raltegravir—Body temperature increased—Sorafenib—thyroid cancer	0.000571	0.00134	CcSEcCtD
Raltegravir—Abdominal pain—Sorafenib—thyroid cancer	0.000571	0.00134	CcSEcCtD
Raltegravir—Renal impairment—Epirubicin—thyroid cancer	0.00057	0.00134	CcSEcCtD
Raltegravir—Hepatic failure—Doxorubicin—thyroid cancer	0.000559	0.00132	CcSEcCtD
Raltegravir—Lethargy—Epirubicin—thyroid cancer	0.000554	0.00131	CcSEcCtD
Raltegravir—Pain in extremity—Epirubicin—thyroid cancer	0.000543	0.00128	CcSEcCtD
Raltegravir—Hot flush—Doxorubicin—thyroid cancer	0.000537	0.00127	CcSEcCtD
Raltegravir—Increased appetite—Doxorubicin—thyroid cancer	0.000534	0.00126	CcSEcCtD
Raltegravir—Migraine—Epirubicin—thyroid cancer	0.000534	0.00126	CcSEcCtD
Raltegravir—Affect lability—Epirubicin—thyroid cancer	0.000534	0.00126	CcSEcCtD
Raltegravir—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000532	0.00125	CcSEcCtD
Raltegravir—Hypersensitivity—Sorafenib—thyroid cancer	0.000532	0.00125	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—SST—thyroid cancer	0.000528	0.0144	CbGpPWpGaD
Raltegravir—Renal impairment—Doxorubicin—thyroid cancer	0.000528	0.00124	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PTCH1—thyroid cancer	0.000524	0.0143	CbGpPWpGaD
Raltegravir—Face oedema—Epirubicin—thyroid cancer	0.000524	0.00123	CcSEcCtD
Raltegravir—Asthenia—Sorafenib—thyroid cancer	0.000518	0.00122	CcSEcCtD
Raltegravir—Mood swings—Epirubicin—thyroid cancer	0.000514	0.00121	CcSEcCtD
Raltegravir—Lethargy—Doxorubicin—thyroid cancer	0.000512	0.00121	CcSEcCtD
Raltegravir—Pruritus—Sorafenib—thyroid cancer	0.000511	0.0012	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—CALCA—thyroid cancer	0.000508	0.0139	CbGpPWpGaD
Raltegravir—Blood creatinine increased—Epirubicin—thyroid cancer	0.000508	0.0012	CcSEcCtD
Raltegravir—Pain in extremity—Doxorubicin—thyroid cancer	0.000502	0.00118	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TCF7L1—thyroid cancer	0.000498	0.0136	CbGpPWpGaD
Raltegravir—Dry skin—Epirubicin—thyroid cancer	0.000497	0.00117	CcSEcCtD
Raltegravir—Abdominal pain upper—Epirubicin—thyroid cancer	0.000496	0.00117	CcSEcCtD
Raltegravir—Migraine—Doxorubicin—thyroid cancer	0.000494	0.00116	CcSEcCtD
Raltegravir—Affect lability—Doxorubicin—thyroid cancer	0.000494	0.00116	CcSEcCtD
Raltegravir—Diarrhoea—Sorafenib—thyroid cancer	0.000494	0.00116	CcSEcCtD
Raltegravir—Breast disorder—Epirubicin—thyroid cancer	0.00049	0.00116	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000489	0.00115	CcSEcCtD
Raltegravir—Nasopharyngitis—Epirubicin—thyroid cancer	0.000485	0.00114	CcSEcCtD
Raltegravir—Face oedema—Doxorubicin—thyroid cancer	0.000485	0.00114	CcSEcCtD
Raltegravir—Gastritis—Epirubicin—thyroid cancer	0.00048	0.00113	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—SST—thyroid cancer	0.00048	0.0131	CbGpPWpGaD
Raltegravir—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000479	0.00113	CcSEcCtD
Raltegravir—Dizziness—Sorafenib—thyroid cancer	0.000477	0.00112	CcSEcCtD
Raltegravir—Mood swings—Doxorubicin—thyroid cancer	0.000476	0.00112	CcSEcCtD
Raltegravir—Abdominal distension—Epirubicin—thyroid cancer	0.000472	0.00111	CcSEcCtD
Raltegravir—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00047	0.00111	CcSEcCtD
Raltegravir—Influenza—Epirubicin—thyroid cancer	0.000469	0.00111	CcSEcCtD
Raltegravir—Eosinophilia—Epirubicin—thyroid cancer	0.000464	0.00109	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CALCA—thyroid cancer	0.000462	0.0126	CbGpPWpGaD
Raltegravir—Dry skin—Doxorubicin—thyroid cancer	0.00046	0.00108	CcSEcCtD
Raltegravir—Vomiting—Sorafenib—thyroid cancer	0.000459	0.00108	CcSEcCtD
Raltegravir—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000459	0.00108	CcSEcCtD
Raltegravir—Rash—Sorafenib—thyroid cancer	0.000455	0.00107	CcSEcCtD
Raltegravir—Dermatitis—Sorafenib—thyroid cancer	0.000455	0.00107	CcSEcCtD
Raltegravir—Breast disorder—Doxorubicin—thyroid cancer	0.000454	0.00107	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—SLC5A5—thyroid cancer	0.000453	0.0124	CbGpPWpGaD
Raltegravir—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000452	0.00107	CcSEcCtD
Raltegravir—Headache—Sorafenib—thyroid cancer	0.000452	0.00107	CcSEcCtD
Raltegravir—Bronchitis—Epirubicin—thyroid cancer	0.000451	0.00106	CcSEcCtD
Raltegravir—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000449	0.00106	CcSEcCtD
Raltegravir—Gastritis—Doxorubicin—thyroid cancer	0.000444	0.00105	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000443	0.00104	CcSEcCtD
Raltegravir—Neutropenia—Epirubicin—thyroid cancer	0.000439	0.00103	CcSEcCtD
Raltegravir—Abdominal distension—Doxorubicin—thyroid cancer	0.000437	0.00103	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000436	0.00103	CcSEcCtD
Raltegravir—Influenza—Doxorubicin—thyroid cancer	0.000434	0.00102	CcSEcCtD
Raltegravir—Eosinophilia—Doxorubicin—thyroid cancer	0.00043	0.00101	CcSEcCtD
Raltegravir—Nausea—Sorafenib—thyroid cancer	0.000429	0.00101	CcSEcCtD
Raltegravir—Weight increased—Epirubicin—thyroid cancer	0.000427	0.00101	CcSEcCtD
Raltegravir—Weight decreased—Epirubicin—thyroid cancer	0.000424	0.001	CcSEcCtD
Raltegravir—Hyperglycaemia—Epirubicin—thyroid cancer	0.000423	0.000997	CcSEcCtD
Raltegravir—Infestation NOS—Epirubicin—thyroid cancer	0.000418	0.000986	CcSEcCtD
Raltegravir—Infestation—Epirubicin—thyroid cancer	0.000418	0.000986	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CDK1—thyroid cancer	0.000418	0.0114	CbGpPWpGaD
Raltegravir—Bronchitis—Doxorubicin—thyroid cancer	0.000417	0.000984	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000415	0.000977	CcSEcCtD
Raltegravir—Renal failure—Epirubicin—thyroid cancer	0.000411	0.000969	CcSEcCtD
Raltegravir—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00041	0.000966	CcSEcCtD
Raltegravir—Neutropenia—Doxorubicin—thyroid cancer	0.000406	0.000956	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000403	0.000951	CcSEcCtD
Raltegravir—Haematuria—Epirubicin—thyroid cancer	0.000399	0.00094	CcSEcCtD
Raltegravir—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000396	0.000932	CcSEcCtD
Raltegravir—Weight increased—Doxorubicin—thyroid cancer	0.000395	0.000931	CcSEcCtD
Raltegravir—Epistaxis—Epirubicin—thyroid cancer	0.000394	0.00093	CcSEcCtD
Raltegravir—Weight decreased—Doxorubicin—thyroid cancer	0.000393	0.000925	CcSEcCtD
Raltegravir—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000391	0.000923	CcSEcCtD
Raltegravir—Infestation—Doxorubicin—thyroid cancer	0.000387	0.000912	CcSEcCtD
Raltegravir—Infestation NOS—Doxorubicin—thyroid cancer	0.000387	0.000912	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000384	0.000904	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—RXRA—thyroid cancer	0.000381	0.0104	CbGpPWpGaD
Raltegravir—Renal failure—Doxorubicin—thyroid cancer	0.00038	0.000896	CcSEcCtD
Raltegravir—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000379	0.000894	CcSEcCtD
Raltegravir—Hepatitis—Epirubicin—thyroid cancer	0.000375	0.000885	CcSEcCtD
Raltegravir—Hypoaesthesia—Epirubicin—thyroid cancer	0.000374	0.00088	CcSEcCtD
Raltegravir—Urinary tract disorder—Epirubicin—thyroid cancer	0.000371	0.000874	CcSEcCtD
Raltegravir—Oedema peripheral—Epirubicin—thyroid cancer	0.00037	0.000872	CcSEcCtD
Raltegravir—Haematuria—Doxorubicin—thyroid cancer	0.000369	0.00087	CcSEcCtD
Raltegravir—Connective tissue disorder—Epirubicin—thyroid cancer	0.000369	0.00087	CcSEcCtD
Raltegravir—Urethral disorder—Epirubicin—thyroid cancer	0.000368	0.000867	CcSEcCtD
Raltegravir—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000366	0.000863	CcSEcCtD
Raltegravir—Epistaxis—Doxorubicin—thyroid cancer	0.000365	0.00086	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TSHR—thyroid cancer	0.000364	0.00995	CbGpPWpGaD
Raltegravir—Visual impairment—Epirubicin—thyroid cancer	0.000362	0.000853	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000358	0.00978	CbGpPWpGaD
Raltegravir—Erythema multiforme—Epirubicin—thyroid cancer	0.000355	0.000837	CcSEcCtD
Raltegravir—Eye disorder—Epirubicin—thyroid cancer	0.000351	0.000827	CcSEcCtD
Raltegravir—Tinnitus—Epirubicin—thyroid cancer	0.00035	0.000825	CcSEcCtD
Raltegravir—Cardiac disorder—Epirubicin—thyroid cancer	0.000348	0.000821	CcSEcCtD
Raltegravir—Hepatitis—Doxorubicin—thyroid cancer	0.000347	0.000819	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000346	0.000815	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000343	0.000809	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MEN1—thyroid cancer	0.000343	0.00935	CbGpPWpGaD
Raltegravir—Oedema peripheral—Doxorubicin—thyroid cancer	0.000342	0.000807	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000341	0.000805	CcSEcCtD
Raltegravir—Angiopathy—Epirubicin—thyroid cancer	0.000341	0.000803	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—thyroid cancer	0.000341	0.000803	CcSEcCtD
Raltegravir—Immune system disorder—Epirubicin—thyroid cancer	0.000339	0.000799	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—thyroid cancer	0.000338	0.000797	CcSEcCtD
Raltegravir—Chills—Epirubicin—thyroid cancer	0.000337	0.000794	CcSEcCtD
Raltegravir—Visual impairment—Doxorubicin—thyroid cancer	0.000335	0.000789	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—RXRA—thyroid cancer	0.000334	0.00912	CbGpPWpGaD
Raltegravir—Alopecia—Epirubicin—thyroid cancer	0.000332	0.000782	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—NRG1—thyroid cancer	0.000329	0.00899	CbGpPWpGaD
Raltegravir—Mental disorder—Epirubicin—thyroid cancer	0.000329	0.000775	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—thyroid cancer	0.000328	0.000774	CcSEcCtD
Raltegravir—Erythema—Epirubicin—thyroid cancer	0.000327	0.00077	CcSEcCtD
Raltegravir—Malnutrition—Epirubicin—thyroid cancer	0.000327	0.00077	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—thyroid cancer	0.000325	0.000765	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—thyroid cancer	0.000324	0.000763	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—thyroid cancer	0.000322	0.00076	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—thyroid cancer	0.000322	0.000759	CcSEcCtD
Raltegravir—Dysgeusia—Epirubicin—thyroid cancer	0.00032	0.000754	CcSEcCtD
Raltegravir—Nervousness—Epirubicin—thyroid cancer	0.000317	0.000748	CcSEcCtD
Raltegravir—Back pain—Epirubicin—thyroid cancer	0.000316	0.000745	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—thyroid cancer	0.000315	0.000743	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—thyroid cancer	0.000314	0.000739	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000313	0.000738	CcSEcCtD
Raltegravir—Chills—Doxorubicin—thyroid cancer	0.000312	0.000735	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PTCH1—thyroid cancer	0.00031	0.00846	CbGpPWpGaD
Raltegravir—Alopecia—Doxorubicin—thyroid cancer	0.000307	0.000723	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—thyroid cancer	0.000304	0.000717	CcSEcCtD
Raltegravir—Ill-defined disorder—Epirubicin—thyroid cancer	0.000303	0.000715	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—thyroid cancer	0.000302	0.000713	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—thyroid cancer	0.000302	0.000713	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—thyroid cancer	0.000302	0.000712	CcSEcCtD
Raltegravir—Agitation—Epirubicin—thyroid cancer	0.0003	0.000708	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—thyroid cancer	0.000298	0.000702	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—thyroid cancer	0.000296	0.000698	CcSEcCtD
Raltegravir—Malaise—Epirubicin—thyroid cancer	0.000295	0.000695	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—thyroid cancer	0.000294	0.000692	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—thyroid cancer	0.000294	0.000692	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—thyroid cancer	0.000292	0.000689	CcSEcCtD
Raltegravir—Palpitations—Epirubicin—thyroid cancer	0.000289	0.000681	CcSEcCtD
Raltegravir—Cough—Epirubicin—thyroid cancer	0.000285	0.000672	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SST—thyroid cancer	0.000283	0.00773	CbGpPWpGaD
Raltegravir—Hypertension—Epirubicin—thyroid cancer	0.000282	0.000665	CcSEcCtD
Raltegravir—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000281	0.000661	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—thyroid cancer	0.000279	0.000659	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—thyroid cancer	0.000278	0.000656	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—thyroid cancer	0.000278	0.000656	CcSEcCtD
Raltegravir—Chest pain—Epirubicin—thyroid cancer	0.000278	0.000656	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—thyroid cancer	0.000278	0.000655	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—thyroid cancer	0.000277	0.000653	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000276	0.000651	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—thyroid cancer	0.000275	0.000648	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CALCA—thyroid cancer	0.000273	0.00745	CbGpPWpGaD
Raltegravir—Malaise—Doxorubicin—thyroid cancer	0.000273	0.000643	CcSEcCtD
Raltegravir—Dry mouth—Epirubicin—thyroid cancer	0.000272	0.000641	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—thyroid cancer	0.000272	0.00064	CcSEcCtD
Raltegravir—Confusional state—Epirubicin—thyroid cancer	0.000269	0.000634	CcSEcCtD
Raltegravir—Palpitations—Doxorubicin—thyroid cancer	0.000267	0.00063	CcSEcCtD
Raltegravir—Infection—Epirubicin—thyroid cancer	0.000265	0.000625	CcSEcCtD
Raltegravir—Cough—Doxorubicin—thyroid cancer	0.000264	0.000622	CcSEcCtD
Raltegravir—Nervous system disorder—Epirubicin—thyroid cancer	0.000262	0.000616	CcSEcCtD
Raltegravir—Thrombocytopenia—Epirubicin—thyroid cancer	0.000261	0.000615	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—thyroid cancer	0.000261	0.000615	CcSEcCtD
Raltegravir—Skin disorder—Epirubicin—thyroid cancer	0.000259	0.000611	CcSEcCtD
Raltegravir—Hyperhidrosis—Epirubicin—thyroid cancer	0.000258	0.000608	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—thyroid cancer	0.000257	0.000607	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—thyroid cancer	0.000257	0.000607	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—thyroid cancer	0.000257	0.000607	CcSEcCtD
Raltegravir—Anxiety—Doxorubicin—thyroid cancer	0.000257	0.000605	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000256	0.000603	CcSEcCtD
Raltegravir—Discomfort—Doxorubicin—thyroid cancer	0.000254	0.000599	CcSEcCtD
Raltegravir—Dry mouth—Doxorubicin—thyroid cancer	0.000252	0.000593	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—thyroid cancer	0.000249	0.000586	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CDK1—thyroid cancer	0.000247	0.00674	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MINPP1—thyroid cancer	0.000245	0.0067	CbGpPWpGaD
Raltegravir—Infection—Doxorubicin—thyroid cancer	0.000245	0.000578	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000243	0.000573	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—thyroid cancer	0.000242	0.00057	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000242	0.00057	CcSEcCtD
Raltegravir—Insomnia—Epirubicin—thyroid cancer	0.000241	0.000569	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—thyroid cancer	0.00024	0.000565	CcSEcCtD
Raltegravir—Paraesthesia—Epirubicin—thyroid cancer	0.00024	0.000564	CcSEcCtD
Raltegravir—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000239	0.000562	CcSEcCtD
Raltegravir—Somnolence—Epirubicin—thyroid cancer	0.000237	0.000559	CcSEcCtD
Raltegravir—Dyspepsia—Epirubicin—thyroid cancer	0.000235	0.000553	CcSEcCtD
Raltegravir—Decreased appetite—Epirubicin—thyroid cancer	0.000232	0.000546	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00023	0.000543	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—thyroid cancer	0.00023	0.000542	CcSEcCtD
Raltegravir—Constipation—Epirubicin—thyroid cancer	0.000228	0.000538	CcSEcCtD
Raltegravir—Pain—Epirubicin—thyroid cancer	0.000228	0.000538	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000225	0.00053	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—thyroid cancer	0.000223	0.000526	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—thyroid cancer	0.000222	0.000522	CcSEcCtD
Raltegravir—Feeling abnormal—Epirubicin—thyroid cancer	0.00022	0.000518	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—thyroid cancer	0.000219	0.000517	CcSEcCtD
Raltegravir—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000218	0.000514	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—thyroid cancer	0.000217	0.000512	CcSEcCtD
Raltegravir—Decreased appetite—Doxorubicin—thyroid cancer	0.000215	0.000506	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000213	0.000502	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—thyroid cancer	0.000213	0.000501	CcSEcCtD
Raltegravir—Urticaria—Epirubicin—thyroid cancer	0.000212	0.000499	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—thyroid cancer	0.000211	0.000497	CcSEcCtD
Raltegravir—Pain—Doxorubicin—thyroid cancer	0.000211	0.000497	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—thyroid cancer	0.000211	0.000497	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—thyroid cancer	0.000211	0.000497	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NDUFA13—thyroid cancer	0.000209	0.0057	CbGpPWpGaD
Raltegravir—Feeling abnormal—Doxorubicin—thyroid cancer	0.000203	0.000479	CcSEcCtD
Raltegravir—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000202	0.000476	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NRG1—thyroid cancer	0.000198	0.00541	CbGpPWpGaD
Raltegravir—Hypersensitivity—Epirubicin—thyroid cancer	0.000197	0.000463	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CHST14—thyroid cancer	0.000196	0.00536	CbGpPWpGaD
Raltegravir—Urticaria—Doxorubicin—thyroid cancer	0.000196	0.000462	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—thyroid cancer	0.000195	0.00046	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—thyroid cancer	0.000195	0.00046	CcSEcCtD
Raltegravir—Asthenia—Epirubicin—thyroid cancer	0.000191	0.000451	CcSEcCtD
Raltegravir—Pruritus—Epirubicin—thyroid cancer	0.000189	0.000445	CcSEcCtD
Raltegravir—Diarrhoea—Epirubicin—thyroid cancer	0.000182	0.00043	CcSEcCtD
Raltegravir—Hypersensitivity—Doxorubicin—thyroid cancer	0.000182	0.000429	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TERT—thyroid cancer	0.000178	0.00486	CbGpPWpGaD
Raltegravir—Asthenia—Doxorubicin—thyroid cancer	0.000177	0.000417	CcSEcCtD
Raltegravir—Dizziness—Epirubicin—thyroid cancer	0.000176	0.000416	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—thyroid cancer	0.000175	0.000412	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HIF1A—thyroid cancer	0.00017	0.00464	CbGpPWpGaD
Raltegravir—Vomiting—Epirubicin—thyroid cancer	0.00017	0.0004	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—thyroid cancer	0.000169	0.000398	CcSEcCtD
Raltegravir—Rash—Epirubicin—thyroid cancer	0.000168	0.000396	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—thyroid cancer	0.000168	0.000396	CcSEcCtD
Raltegravir—Headache—Epirubicin—thyroid cancer	0.000167	0.000394	CcSEcCtD
Raltegravir—Dizziness—Doxorubicin—thyroid cancer	0.000163	0.000385	CcSEcCtD
Raltegravir—Nausea—Epirubicin—thyroid cancer	0.000158	0.000373	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—HPGD—thyroid cancer	0.000158	0.00432	CbGpPWpGaD
Raltegravir—Vomiting—Doxorubicin—thyroid cancer	0.000157	0.00037	CcSEcCtD
Raltegravir—Rash—Doxorubicin—thyroid cancer	0.000156	0.000367	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—thyroid cancer	0.000155	0.000366	CcSEcCtD
Raltegravir—Headache—Doxorubicin—thyroid cancer	0.000155	0.000364	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—NRAS—thyroid cancer	0.00015	0.00409	CbGpPWpGaD
Raltegravir—Nausea—Doxorubicin—thyroid cancer	0.000147	0.000345	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—BRAF—thyroid cancer	0.000141	0.00385	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—KRAS—thyroid cancer	0.000129	0.00352	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—HRAS—thyroid cancer	0.00011	0.00299	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—thyroid cancer	0.000107	0.00291	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCND1—thyroid cancer	0.000103	0.00281	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTEN—thyroid cancer	9.93e-05	0.00271	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKT1—thyroid cancer	9.68e-05	0.00264	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TPR—thyroid cancer	9.08e-05	0.00248	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PRKAR1A—thyroid cancer	8.94e-05	0.00244	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NRAS—thyroid cancer	8.86e-05	0.00242	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KRAS—thyroid cancer	7.62e-05	0.00208	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC5A5—thyroid cancer	6.8e-05	0.00186	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—thyroid cancer	6.77e-05	0.00185	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HRAS—thyroid cancer	6.48e-05	0.00177	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKT1—thyroid cancer	5.72e-05	0.00156	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—RXRA—thyroid cancer	5.71e-05	0.00156	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARG—thyroid cancer	3.61e-05	0.000985	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—thyroid cancer	2.84e-05	0.000775	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTEN—thyroid cancer	2.47e-05	0.000676	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—thyroid cancer	1.43e-05	0.000389	CbGpPWpGaD
